|
1
|
O'Connell MJ: Current status of adjuvant
therapy for colorectal cancer. Oncology (Williston Park).
18:751–755; discussion 755–758. 2004.PubMed/NCBI
|
|
2
|
Almendro V, Ametller E, García-Recio S,
Collazo O, Casas I, Augé JM, Maurel J and Gascón P: The role of
MMP7 and its cross-talk with the FAS/FASL system during the
acquisition of chemoresistance to oxaliplatin. PLoS One.
4:e47282009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yardley DA: Drug resistance and the role
of combination chemotherapy in improving patient outcomes. Int J
Breast Cancer. 2013:1374142013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Buchbinder EI and Desai A: CTLA-4 and PD-1
pathways: Similarities, differences, and implications of their
inhibition. Am J Clin Oncol. 39:98–106. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gravett AM, Dalgleish AG and Copier J: In
vitro culture with gemcitabine augments death receptor and NKG2D
ligand expression on tumour cells. Sci Rep. 9:15442019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Scott KA, Dalgleish AG and Liu WM: The
combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the
anticancer effects of radiation in an orthotopic murine glioma
model. Mol Cancer Ther. 13:2955–2967. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gravett AM, Trautwein N, Stevanović S,
Dalgleish AG and Copier J: Gemcitabine alters the proteasome
composition and immunopeptidome of tumour cells. Oncoimmunology.
7:e14381072018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nars MS and Kaneno R: Immunomodulatory
effects of low dose chemotherapy and perspectives of its
combination with immunotherapy. Int J Cancer. 132:2471–2478. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsimberidou AM, Eggermont AM and Schilsky
RL: Precision cancer medicine: The future is now, only better. Am
Soc Clin Oncol Educ Book. 2014:61–69. 2014. View Article : Google Scholar
|
|
10
|
Hu HM, Zhao X, Kaushik S, Robillard L,
Barthelet A, Lin KK, Shah KN, Simmons AD, Raponi M, Harding TC and
Bandyopadhyay S: A quantitative chemotherapy genetic interaction
map reveals factors associated with PARP inhibitor resistance. Cell
Rep. 23:918–929. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McKenna MT, Weis JA, Brock A, Quaranta V
and Yankeelov TE: Precision medicine with imprecise therapy:
Computational modeling for chemotherapy in breast cancer. Transl
Oncol. 11:732–742. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Deng X and Nakamura Y: Cancer precision
medicine: From cancer screening to drug selection and personalized
immunotherapy. Trends Pharmacol Sci. 38:15–24. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pan B and Lentzsch S: The application and
biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol
Ther. 136:56–68. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hideshima T, Chauhan D, Shima Y, Raje N,
Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, et
al: Thalidomide and its analogs overcome drug resistance of human
multiple myeloma cells to conventional therapy. Blood.
96:2943–2950. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu WM, Gravett AM and Dalgleish AG: The
antimalarial agent artesunate possesses anticancer properties that
can be enhanced by combination strategies. Int J Cancer.
128:1471–1480. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gravett AM, Liu WM, Krishna S, Chan WC,
Haynes RK, Wilson NL and Dalgleish AG: In vitro study of the
anti-cancer effects of artemisone alone or in combination with
other chemotherapeutic agents. Cancer Chemother Pharmacol.
67:569–577. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hamacher-Brady A, Stein HA, Turschner S,
Toegel I, Mora R, Jennewein N, Efferth T, Eils R and Brady NR:
Artesunate activates mitochondrial apoptosis in breast cancer cells
via iron-catalyzed lysosomal reactive oxygen species production. J
Biol Chem. 286:6587–6601. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang ND, Tan SH, Ng S, Shi Y, Zhou J, Tan
KS, Wong WS and Shen HM: Artesunate induces cell death in human
cancer cells via enhancing lysosomal function and lysosomal
degradation of ferritin. J Biol Chem. 289:33425–33441. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology. The gene
ontology consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
The Gene Ontology Consortium: The gene
ontology resource: 20 Years and still GOing strong. Nucleic Acids
Res. 47:D330–D338. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mi H, Huang X, Muruganujan A, Tang H,
Mills C, Kang D and Thomas PD: PANTHER version 11: Expanded
annotation data from gene ontology and reactome pathways, and data
analysis tool enhancements. Nucleic Acids Res. 45:D183–D189. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Scott KA, Dalgleish AG and Liu WM:
Anticancer effects of phytocannabinoids used with chemotherapy in
leukaemia cells can be improved by altering the sequence of their
administration. Int J Oncol. 51:369–377. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wallqvist A, Rabow AA, Shoemaker RH,
Sausville EA and Covell DG: Establishing connections between
microarray expression data and chemotherapeutic cancer
pharmacology. Mol Cancer Ther. 1:311–320. 2002.PubMed/NCBI
|
|
24
|
Tseng AH, Chung FH, Lee HC, Wu LC, Chen CH
and Su LJ: Microarray analysis and establishment of drug screening
platform using 5-fluorouracil resistance HCT116 colon cancer cells.
Genomic Med Biomarkers Health Sci. 4:21–27. 2012. View Article : Google Scholar
|
|
25
|
Lønning PE, Sørlie T, Perou CM, Brown PO,
Botstein D and Børresen-Dale AL: Microarrays in primary breast
cancer-lessons from chemotherapy studies. Endocr Relat Cancer.
8:259–263. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kao KJ, Chang KM, Hsu HC and Huang AT:
Correlation of microarray-based breast cancer molecular subtypes
and clinical outcomes: Implications for treatment optimization. BMC
Cancer. 11:1432011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kamel HF and Al-Amodi HS: Exploitation of
gene expression and cancer biomarkers in paving the path to era of
personalized medicine. Genomics Proteomics Bioinformatics.
15:220–235. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang TH and Chao A: Microarray analysis of
gene expression of cancer to guide the use of chemotherapeutics.
Taiwan J Obstet Gynecol. 46:222–229. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pritchard JR, Bruno PM, Gilbert LA, Capron
KL, Lauffenburger DA and Hemann MT: Defining principles of
combination drug mechanisms of action. Proc Natl Acad Sci USA.
110:E170–E179. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu WM, Scott KA, Dennis JL, Kaminska E,
Levett AJ and Dalgleish AG: Naltrexone at low doses upregulates a
unique gene expression not seen with normal doses: Implications for
its use in cancer therapy. Int J Oncol. 49:793–802. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fink EC and Ebert BL: The novel mechanism
of lenalidomide activity. Blood. 126:2366–2369. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jackson SP and Bartek J: The DNA-damage
response in human biology and disease. Nature. 461:1071–1078. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu WM: Enhancing the cytotoxic activity
of novel targeted therapies-is there a role for a combinatorial
approach? Curr Clin Pharmacol. 3:108–117. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Housman G, Byler S, Heerboth S, Lapinska
K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: An
overview. Cancers (Basel). 6:1769–1792. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rixe O, Ortuzar W, Alvarez M, Parker R,
Reed E, Paull K and Fojo T: Oxaliplatin, tetraplatin, cisplatin,
and carboplatin: Spectrum of activity in drug-resistant cell lines
and in the cell lines of the national cancer institute's anticancer
drug screen panel. Biochem Pharmacol. 52:1855–1865. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shah MA and Schwartz GK: The relevance of
drug sequence in combination chemotherapy. Drug Resist Updat.
3:335–356. 2000. View Article : Google Scholar : PubMed/NCBI
|
